Skye Bioscience’s nimacimab blocks CB1, the same receptor targeted by an obesity drug candidate now in the hands of Novo Nordisk. But Skye contends its Phase 2-ready antibody drug has several advantages over the small molecule that joined Novo’s pipeline in a deal valued at $1 billion.
The drug showed positive results in a 210-patient study in patients experiencing treatment-resistant seizures from tuberous sclerosis complex, a rare form of epilepsy.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Los Angeles startup Kalytera Therapeutics is taking the high out of the THC – refining cannabinoids so they can have broader therapeutic applications in conditions like osteoporosis, Prader-Willi syndrome, PTSD, obesity and weight loss associated with cancer. Kalytera just raised $500,000 in seed funding, according to a regulatory filing. There’s a litany of potential applications for […]